Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians-Reference-Cited by-同舟云学术

Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians

Published:2023-09-15 Issue:12 Volume:102 Page:3639-3641
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Dieterle Martin Philipp,Mostufi-Zadeh-Haghighi Gila,Kus Jan Wilhelm,Wippel Christopher,Brugger Zacharias,Miething Cornelius,Wäsch Ralph,Engelhardt Monika^ORCID

Funder

Universitätsklinikum Freiburg

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05451-8.pdf

Reference10 articles.

1. Shrivastava T, Van Rhee F, Al Hadidi S (2023) Targeting B cell maturation antigen in patients with multiple myeloma: current perspectives. Onco Targets Ther 16:441–464. https://doi.org/10.2147/ott.s370880

2. Moreau P, van de Donk NWCJ, Delforge M et al (2023) Comparative Efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and/or refractory multiple myeloma. Adv Ther 40:2412–2425. https://doi.org/10.1007/s12325-023-02480-7

3. Usmani SZ, Garfall AL, van de Donk NWCJ et al (2021) Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398:665–674. https://doi.org/10.1016/S0140-6736(21)01338-6

4. Mateos MV, Chari A, Usmani SZ et al (2023) Comparative efficacy of teclistamab versus physician’s choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 23:385–393. https://doi.org/10.1016/J.CLML.2023.02.006

5. Engelhardt M, Dold SM, Ihorst G et al (2016) Geriatric assessment in multiple myeloma patients: Validation of the international Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica 101:1110–1119. https://doi.org/10.3324/haematol.2016.148189